Heterogeneous nuclear ribonucleoprotein A0 (hnRNP A0)

Heterogeneous nuclear ribonucleoprotein A0 (hnRNP A0) is a member of the hnRNP A/B subfamily of RNA-binding proteins responsible for binding heterogeneous nuclear RNA and regulating various aspects of RNA metabolism, particularly pre-mRNA processing, transport, and stability[1][2]. It is primarily nuclear but can shuttle between the nucleus and cytoplasm. hnRNP A0 binds preferentially to AU-rich elements in mRNA and plays a pivotal role in post-transcriptional regulation, such as the stabilization and alternative splicing of specific transcripts (notably cytokine and mitotic regulators)[1][6]. Phosphorylation of hnRNP A0 alters its activity, particularly in cancer, where it can promote cell proliferation and inhibit apoptosis. Abnormal expression or mutation of hnRNP A0 is implicated in cancer development and progression, especially in malignancies with specific chromosomal abnormalities (e.g., 5q deletions in myeloid neoplasms). hnRNP A0 is considered a potential prognostic biomarker and therapeutic target in oncology[3][6]. Drug development is ongoing, focusing mainly on non-specific or natural compounds; no direct, approved inhibitors currently exist. The essential roles of hnRNP A0 in normal RNA biology underscore significant therapeutic challenges.

Other names

HNRNPA0HNRPA0hnRNP A0heterogeneous nuclear ribonucleoprotein A0hnRNA binding protein

RNA binding and post-transcriptional regulation of gene expression Phosphorylation-dependent modulation of mRNA targets in cancer Modulation of cancer cell growth, mitosis, and apoptosis Regulation of alternative splicing and mRNA nuclear export (for example, affecting HIV-1 mRNA processing)[4]